Article in Frontiers in physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
3 authors.
Mark J RanekDepartment of Medicine, Division of Cardiology, The Johns Hopkins Medical Institutions, Baltimore, MD, United States.
Md Shenuarin BhuiyanDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center, Shreveport, LA, United States.
Xuejun WangDivision of Basic Biomedical Sciences, The University of South Dakota Sanford School of Medicine, Vermillion, SD, United States.
Funding
Ubiquitin receptors and cardiac proteotoxicityR01HL072166 · NHLBI · UNIVERSITY OF SOUTH DAKOTA · PI WANG, XUEJUN · 2003 to 2023
$6.9M
The COP9 SIgnalosome in the HeartR01HL085629 · NHLBI · UNIVERSITY OF SOUTH DAKOTA · PI WANG, XUEJUN · 2006 to 2019
$4.7M
Cardiac Pathophysiology of Proteasome PhosphoregulationR01HL153614 · NHLBI · UNIVERSITY OF SOUTH DAKOTA · PI XUEJUN WANG · 2020 to 2026
$2.9M
Sigmar1 in lipid metabolismR01HL145753 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI BHUIYAN, MD. SHENUARIN · 2019 to 2023
$2.6M
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal DegradationR01HL131667 · NHLBI · UNIVERSITY OF SOUTH DAKOTA · PI CUI, TAIXING, WANG, XUEJUN · 2017 to 2020
$1.4M
Sigma-1 receptor and cardioprotectionR00HL122354 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI BHUIYAN, MD. SHENUARIN · 2015 to 2017
$747k
VAL-0914 Decreases PAO to Protect Against Cardiac ProteinopathiesR41HL152919 · NHLBI · ENABLE THERAPEUTICS LLC · PI SHAFFER, ROBERT, WANG, XUEJUN · 2021 to 2021
$450k
Sigma-1 receptor and cardioprotectionK99HL122354 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI BHUIYAN, MD. SHENUARIN · 2014 to 2015
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Editorial: Targeting Cardiac Proteotoxicity. · full record | OpenQuestion